XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsOn October 27, 2022, the Company announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision was based on the Company's assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines. The Company will continue to participate in the World Health Organization’s Solidarity Trial Vaccines, which is an international, multi-center, multi-vaccine, adaptive, shared placebo, event-driven, individually randomized controlled clinical trial evaluating the efficacy and safety of potential COVID-19 vaccines. The Company will also continue preclinical work on a pan-COVID-19 vaccine candidate. In addition, as described in Note 15 above, the Company's collaborator, Advaccine, will continue to develop INO-4800 as a COVID-19 heterologous booster vaccine in Greater China with its own resources.